The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Fall 2021 RFP: Accelerating Early Proof-of-Concept Testing of Promising PD Therapies, 2021Testing the Neuroprotective Effects of Modulating Atp6v0a1
Study Rationale: Parkinson’s disease (PD) is associated with the death of dopamine-producing neurons. Neuroprotective strategies that could maintain these critical cells would provide a much-needed...
-
Alpha-synuclein Seed Amplification Assay Program, 2021Development of a Simplified, Rapid Method for Measuring Alpha-synuclein in Clinical Samples
Study Rationale: Alpha-synuclein aggregates are considered to be an excellent biomarker for the diagnosis of Parkinson’s disease (PD). The challenge is to optimize the tests currently used to detect...
-
Fall 2021 RFP: Outcome Measures, 2021Development and Validation of a Sensitive Method for Measuring PINK
Study Rationale: Mutations in PINK1 are linked to familial Parkinson’s disease (PD), but their role in sporadic forms of the disorder are not clear. The PINK1 protein works with PRKN to dispose of...
-
Fall 2021 RFP: Expanding Biological Understanding of PD, 2021Studying How Defects in Autophagy Contribute to the Aggregation of Alpha-synuclein in Neurons with LRRK2 Mutations
Study Rationale: Mutations in the LRRK2 gene are the most frequent cause of inherited forms of Parkinson’s disease (PD). We have found that these mutations disrupt autophagy—a process that cells...
-
Fall 2021 RFP: Outcome Measures, 2021Exploring the Role of Faulty Protein Degradation as a Cause of Parkinson’s Disease
Study Rationale: For the brain to work efficiently, its cells have systems to clear out old proteins that are no longer needed or functional. When these protein-clearing systems fail, old proteins...
-
Fall 2021 RFP: Accelerating Early Proof-of-Concept Testing of Promising PD Therapies, 2021Development of an Inhibitor of Tau Aggregation to Treat Parkinson’s Disease
Study Rationale: The formation of tau aggregates is caused by excessive modification and abnormal folding of the tau protein in the brain, which leads to cellular dysfunction and neurodegeneration...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.